List of Excipients in Branded Drug VEKLURY

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Gilead Sciences Inc	VEKLURY	remdesivir	61958-2902	BETADEX SULFOBUTYL ETHER SODIUM	2032-06-08
Gilead Sciences Inc	VEKLURY	remdesivir	61958-2902	HYDROCHLORIC ACID	2032-06-08
Gilead Sciences Inc	VEKLURY	remdesivir	61958-2902	SODIUM HYDROXIDE	2032-06-08
Gilead Sciences Inc	VEKLURY	remdesivir	61958-2902	WATER	2032-06-08

Veklury Excipient Strategy and Commercial Opportunities for Remdesivir

Last updated: August 2, 2026

Veklury is an intravenous remdesivir product whose commercial performance depends on more than the antiviral active ingredient. Its formulation uses sulfobutylether-beta-cyclodextrin sodium, or SBECD, to improve aqueous solubility. The main excipient opportunities are supply security, lower-volume presentations, ready-to-use administration formats, pediatric and outpatient products, and manufacturing platforms that reduce preparation steps.

The highest-value opportunity is a differentiated remdesivir presentation that preserves Veklury’s clinical and regulatory profile while reducing pharmacy labor, vial waste, cold-chain complexity, or dependence on large quantities of SBECD. A direct generic substitution strategy is less attractive because Veklury’s formulation, manufacturing process, regulatory history, and patent estate create barriers beyond active-ingredient synthesis.

What excipients are used in Veklury?

Veklury contains remdesivir and SBECD as the principal formulation components. Hydrochloric acid and sodium hydroxide are used for pH adjustment. The product is supplied as either a lyophilized powder or a concentrated solution for dilution before intravenous infusion.

Veklury presentation	Remdesivir content	Principal excipient	Approximate excipient quantity
Lyophilized powder vial	100 mg	SBECD sodium	3,000 mg per vial
Injection, 100 mg/20 mL	100 mg	SBECD sodium	6,000 mg per vial
Diluted infusion	100 mg dose	Sodium chloride infusion diluent	Prepared by healthcare provider

The lyophilized product is reconstituted with sterile water for injection and then diluted in 0.9% sodium chloride. The solution product is diluted directly in sodium chloride before administration. The prescribing information identifies SBECD, hydrochloric acid, and sodium hydroxide as inactive ingredients. [1]

Why does Veklury use SBECD?

Remdesivir has limited aqueous solubility. SBECD is a modified cyclodextrin that forms inclusion complexes with hydrophobic drug molecules. This increases apparent solubility and supports an aqueous intravenous dosage form.

SBECD is widely used in parenteral medicines, including itraconazole injection. It is attractive for remdesivir because it provides:

• High drug-solubilization capacity.
• Compatibility with aqueous intravenous administration.
• Established pharmaceutical manufacturing precedent.
• A relatively well-characterized safety and regulatory profile.
• A practical route to both lyophilized and liquid presentations.

The tradeoff is excipient load. The solution presentation contains substantially more SBECD per vial than the lyophilized presentation. That difference affects procurement, fill volume, shipping weight, cost of goods, and perceptions about use in patients with renal impairment.

What is the Veklury formulation strategy?

Veklury uses two formulation approaches to support different hospital workflows.

Lyophilized powder

The powder presentation has a lower SBECD quantity per 100 mg dose and generally offers better long-term storage flexibility than a ready-made liquid. Its disadvantages are reconstitution time, aseptic manipulation, potential preparation errors, and additional pharmacy labor.

The powder is commercially useful where:

• Hospital pharmacies prefer lower storage volume.
• Demand is variable.
• Inventory turnover is slower.
• Transportation and storage efficiency matter.
• The institution already has established sterile-compounding procedures.

Concentrated solution

The 100 mg/20 mL solution removes the reconstitution step. It can improve preparation speed and reduce manipulation in high-throughput hospital pharmacies. Its disadvantages include higher SBECD exposure per vial, greater liquid shipping volume, and potentially higher packaging and cold-chain costs.

The solution is commercially attractive where:

• Rapid preparation is important.
• Outpatient or short-stay infusion is expanding.
• Pharmacy labor costs are high.
• The provider prefers fewer preparation steps.
• Dose scheduling is predictable.

The two presentations illustrate a central excipient-commercialization tradeoff: lower excipient mass and storage burden versus faster preparation and simpler use.

How much SBECD does Veklury require?

The lyophilized powder contains approximately 3 grams of SBECD per 100 mg vial. The concentrated solution contains approximately 6 grams per 100 mg vial. A standard adult course therefore creates a meaningful difference in total excipient exposure.

For a three-day outpatient regimen using one 100 mg dose daily, the approximate SBECD amounts are:

Course	Powder presentation	Solution presentation
One 100 mg dose	3 g SBECD	6 g SBECD
Three-day course	9 g SBECD	18 g SBECD
Five-day course	15 g SBECD	30 g SBECD

These amounts exclude any differences caused by dose adjustments, discarded product, or institutional preparation practices.

The FDA expanded Veklury’s use in July 2023 to include patients with severe renal impairment, including those receiving dialysis, without a dose adjustment. The label change reduced a major commercial objection to SBECD-containing remdesivir products. It did not eliminate the importance of SBECD sourcing, toxicological documentation, or manufacturing control. [2]

What commercial opportunities exist for Veklury excipients?

1. SBECD supply and dual sourcing

SBECD is the most strategically important excipient in the Veklury formulation. A supplier with qualified pharmaceutical-grade material, validated impurity controls, and capacity for large-scale sterile drug manufacturing can capture value even without owning remdesivir intellectual property.

Potential supplier advantages include:

• Dual-site manufacturing.
• Regulatory support for drug-master-file submissions.
• Low endotoxin and bioburden performance.
• Consistent degree of substitution.
• Tight control of residual solvents and elemental impurities.
• Reliable batch-to-batch complexation performance.
• Capacity reserved for pandemic or demand shocks.

SBECD supply is a higher-value opportunity than commodity sodium chloride or pH adjusters because it is formulation-critical and not readily replaceable without redevelopment.

2. Alternative cyclodextrins

Other cyclodextrins, including hydroxypropyl-beta-cyclodextrin, may be evaluated as substitutes or co-solubilizers. Their commercial value depends on whether they can match SBECD for:

• Remdesivir solubilization.
• Chemical stability.
• Infusion compatibility.
• Hemolysis and local tolerability.
• Renal safety.
• Extractables and leachables profile.
• Lyophilization behavior.
• Regulatory precedent.

An alternative cyclodextrin would require comparative formulation, toxicology, stability, and clinical bridging work. It is therefore a medium- to long-term opportunity rather than a near-term drop-in replacement.

3. Ready-to-use infusion bags

A premixed remdesivir infusion bag could eliminate vial reconstitution and dilution. This format could be valuable in outpatient infusion centers, emergency departments, and hospitals with high remdesivir throughput.

The key technical issues are:

• Stability in the final infusion container.
• Adsorption to bag and tubing materials.
• Particulate formation.
• Container-closure integrity.
• Sterility assurance.
• Light sensitivity.
• Compatibility with common infusion sets.
• Maximum allowable storage time after dilution.

A ready-to-use bag could also reduce dosing errors and shorten administration preparation. Its commercial disadvantage is a larger shipping footprint and more demanding packaging validation.

4. Smaller-volume liquid products

The existing concentrated solution is supplied in a 20 mL vial. A higher-concentration product could reduce vial volume and SBECD mass if the solubility and tolerability profile permitted it.

This strategy would require evidence that a higher remdesivir concentration does not create:

• Precipitation risk.
• Increased infusion-site reactions.
• Greater osmolality concerns.
• More difficult manufacturing.
• Reduced stability.
• Increased risk of dosing errors.

A smaller-volume product could have strong value in ambulatory settings, where storage and handling constraints are more severe than in large hospitals.

5. Pediatric presentations

Veklury is approved for adults and pediatric patients at least 28 days old and weighing at least 3 kg, subject to the approved treatment criteria. Pediatric dosing creates a demand for accurate low-volume administration and flexible dose preparation. [1]

Commercial opportunities include:

• Low-dead-volume transfer devices.
• More accurate dose-measuring systems.
• Ready-to-dilute pediatric containers.
• Reduced-vial-waste formats.
• Formulations optimized for small doses.

A pediatric-specific formulation would face stricter scrutiny around dosing accuracy, preservative use, infusion compatibility, and excipient exposure per kilogram.

6. Device-linked administration systems

A closed-system transfer device or preassembled administration kit could reduce manipulation in pharmacies and infusion centers. The value proposition is operational rather than pharmacological.

Relevant components include:

• Vial adapters.
• Transfer spikes.
• Filtered administration sets.
• Premixed diluent systems.
• Barcode-enabled dose preparation.
• Low-retention syringes and tubing.

Device combinations may create separate intellectual-property opportunities, but they must be assessed against hospital purchasing practices and reimbursement economics.

What patents protect Veklury’s formulation and manufacturing?

The principal commercial protection around Veklury is associated with remdesivir, its prodrug chemistry, therapeutic use, and manufacturing. Excipient suppliers generally do not need to own the active-ingredient patent estate to sell SBECD or standard formulation components, but a finished-product developer must assess freedom to operate.

Formulation patent considerations

A formulation patent may cover:

• Remdesivir with a specified cyclodextrin.
• Defined remdesivir-to-SBECD ratios.
• A particular pH range.
• Lyophilized cake characteristics.
• Reconstitution behavior.
• Stability limits.
• Specific impurity thresholds.
• Container-closure systems.
• Infusion preparation methods.

Not every Veklury excipient or process detail is necessarily protected by an Orange Book-listed patent. FDA Orange Book listings are product-specific and do not capture every trade secret, manufacturing control, supplier qualification, or unlisted process right. [3]

Manufacturing barriers

The main manufacturing barriers are likely to include:

• Control of remdesivir degradation products.
• Sterile filtration and aseptic fill-finish.
• Lyophilization-cycle development.
• SBECD complexation consistency.
• Control of water content in the powder.
• Reconstitution time.
• Stability after dilution.
• Scale-up of a high-value sterile product.
• Validation of container and closure materials.

A competitor can avoid a narrow formulation claim and still face substantial development risk if its product requires a different excipient system or manufacturing process.

When does Veklury lose exclusivity?

Veklury’s exclusivity position includes FDA regulatory exclusivity, patents covering remdesivir-related technology, and practical barriers to developing an injectable generic. These protections operate on different timelines.

Protection category	Commercial effect
New chemical entity exclusivity	Delays certain ANDA approvals during the statutory period
Orphan or pediatric-related exclusivity, if applicable	Can extend protection for specific indications or populations
Listed patents	Can trigger Paragraph IV litigation and a potential 30-month stay
Process and formulation know-how	May remain commercially relevant after patent expiry
Injectable-product complexity	Raises development and manufacturing costs

The FDA approved Veklury in October 2020 for adults and pediatric patients at least 12 years old and weighing at least 40 kg who required hospitalization for COVID-19. The approval was later expanded to younger and lighter pediatric patients, and to patients with renal impairment. [4]

Exact generic-entry timing depends on the current Orange Book patent listing, any applicable regulatory exclusivity, ANDA filing dates, Paragraph IV certifications, litigation outcomes, and settlement terms. A patent expiration date alone does not determine market entry.

Are there Paragraph IV challenges to Veklury?

A Paragraph IV challenge would involve an ANDA applicant asserting that a listed patent is invalid, unenforceable, or not infringed. The commercial consequences would depend on:

• The specific patent challenged.
• Whether the applicant seeks approval for all approved uses.
• Whether Gilead files suit within 45 days.
• Whether a statutory 30-month stay applies.
• Whether the litigation concerns active ingredient, formulation, use, or manufacturing claims.
• Whether the parties reach a launch settlement.

For Veklury, the principal risk is likely to arise from a complex injectable product rather than from a simple oral generic. An ANDA applicant must demonstrate pharmaceutical equivalence, bioequivalence or applicable alternatives, sterility, stability, container compatibility, and manufacturing consistency.

Publicly reported Paragraph IV activity, litigation, and settlement terms should be evaluated against current FDA and court records rather than inferred from the existence of remdesivir patents. A formulation-focused challenge could have greater commercial significance than a challenge directed only at a broad chemical claim if the ANDA uses the same SBECD-based product architecture.

What is the Orange Book status of Veklury?

Veklury is an FDA-approved prescription injectable product. The relevant Orange Book analysis concerns:

• Approved product specifications.
• Listed patents, if any.
• Patent-use codes.
• Regulatory exclusivity.
• Whether an ANDA applicant can certify against each listed patent.
• Whether the proposed generic uses the same formulation and route.

Orange Book data should be read together with the Veklury prescribing information and FDA approval history. Orange Book status does not disclose all manufacturing know-how or every patent that could affect a competing product. [3]

How strong is the Veklury patent estate?

The estate is strongest where it combines remdesivir chemistry with therapeutic-use claims and manufacturing controls. It is weaker for commodity excipients that can be purchased independently and used in a non-infringing formulation.

Estate component	Relative barrier	Commercial assessment
Remdesivir active-ingredient chemistry	High	Central to product substitution
Therapeutic-use claims	Medium to high	Scope depends on indication and claim construction
SBECD excipient itself	Low	Broad commercial availability
Specific SBECD formulation	Medium	Depends on claim scope and prior art
Lyophilization process	Medium	Can create technical and manufacturing barriers
Ready-to-use infusion format	Medium	Opportunity for differentiated products
Manufacturing know-how	High in practice	Difficult to replicate from public documents alone

The most defensible commercial position may come from a combination of formulation patents, process controls, supplier agreements, and regulatory data rather than from an excipient patent alone.

Which companies are competing with Veklury?

Veklury competes primarily with other COVID-19 therapies and with changing treatment guidelines rather than with another directly substitutable injectable remdesivir product.

The relevant competitive groups are:

• Oral antiviral manufacturers, including Pfizer’s Paxlovid and Merck’s Lagevrio.
• Generic and contract manufacturers evaluating remdesivir supply.
• Suppliers of SBECD and alternative cyclodextrins.
• Infusion-service providers.
• Hospital pharmacies seeking lower-cost or easier-to-administer presentations.
• Potential regional manufacturers operating under voluntary or government-supported licensing arrangements.

Paxlovid has a major convenience advantage because it is orally administered. Veklury retains a role where intravenous therapy is clinically preferred, oral treatment is unsuitable, or patients are already receiving hospital-based care. The excipient opportunity is therefore linked to administration efficiency and patient access, not only to active-ingredient cost.

What revenue exposure does Veklury create for Gilead?

Veklury generated approximately $2.2 billion in Gilead product sales during 2023, down from the exceptional pandemic-period revenue peak. [5] The product remains commercially relevant because COVID-19 hospitalization and high-risk outpatient treatment continue to generate demand, although volumes are more difficult to forecast than for chronic therapies.

Excipient-related commercial exposure includes:

• SBECD price and supply volatility.
• Vial and stopper costs.
• Lyophilization capacity.
• Sterile fill-finish utilization.
• Waste from unused portions or canceled doses.
• Hospital labor associated with preparation.
• Demand shifts between inpatient and outpatient treatment.
• Product mix between powder and solution.

A lower-cost excipient strategy could improve gross margin, but a ready-to-use presentation may create greater value by reducing hospital labor and preparation complexity.

What generic launch scenarios exist for Veklury?

Scenario 1: Delayed injectable generic

A competitor launches after patent and regulatory barriers decline. The product uses an SBECD-based formulation and competes primarily on price. This is the most conventional scenario but may require substantial sterile manufacturing investment.

Scenario 2: Authorized or licensed competition

A remdesivir product enters through a license, settlement, or regional access arrangement. This could reduce litigation risk and accelerate supply in selected markets.

Scenario 3: Differentiated formulation

A competitor launches a lower-volume, ready-to-use, pediatric, or stability-enhanced presentation. The product competes on workflow and total treatment cost rather than unit price.

Scenario 4: Excipient-led platform licensing

An excipient company licenses a cyclodextrin system, premix technology, or container-device combination to a finished-dose manufacturer. The excipient provider earns value without directly commercializing remdesivir.

The third and fourth scenarios offer the clearest opportunities for specialized formulation companies.

What geographic opportunities exist for Veklury excipients?

The United States and European Union have the strongest regulatory precedent for SBECD-based intravenous products. Emerging markets may offer more immediate opportunities for local sterile manufacturing, provided the developer can satisfy national registration requirements and supply reliable pharmaceutical-grade excipient.

Geographic priorities include:

• North America: high regulatory standards and hospital purchasing sophistication.
• European Union: centralized and national regulatory pathways with strong demand for supply resilience.
• Japan and South Korea: high-quality injectable manufacturing and advanced hospital systems.
• India: established generic and contract-manufacturing capabilities.
• China: large API and excipient manufacturing base, with regulatory and export qualification requirements.
• Latin America: potential demand for lower-cost remdesivir products and regional fill-finish.

Local manufacturing may reduce freight costs but does not remove the need for validated sterile processes, qualified SBECD, and regulatory comparability.

Key Takeaways

• SBECD is the critical excipient in Veklury and the most important formulation-related commercial opportunity.
• The lyophilized powder uses approximately 3 grams of SBECD per 100 mg vial; the concentrated solution uses approximately 6 grams.
• Ready-to-use bags, smaller-volume liquids, pediatric formats, and device-linked administration systems offer higher differentiation than a basic SBECD substitute.
• FDA approval for use in severe renal impairment reduced a major barrier associated with SBECD-containing remdesivir.
• Excipient suppliers can participate without owning remdesivir patents, but finished-product developers must assess active-ingredient, formulation, use, process, and manufacturing rights.
• Generic competition will likely be constrained by sterile manufacturing, stability, regulatory comparability, and litigation risk.
• The strongest commercial strategy is a formulation or delivery improvement that reduces total treatment cost, pharmacy labor, waste, or supply-chain exposure.

FAQs About Veklury Excipient and Formulation Opportunities

Can SBECD be replaced in a generic Veklury formulation?

Potentially, but a replacement would require comparative solubility, stability, safety, infusion compatibility, and regulatory studies. SBECD has the strongest precedent for the current product architecture.

Does the Veklury solution have more SBECD than the powder?

Yes. The solution contains approximately 6 grams of SBECD per 100 mg vial, compared with approximately 3 grams in the lyophilized powder vial.

Is SBECD a patent-protected ingredient?

SBECD is a commercially established excipient and is not, by itself, the principal barrier to remdesivir competition. Specific formulation combinations or manufacturing processes may carry separate patent risk.

Could a premixed Veklury infusion bag improve hospital economics?

Yes. A premixed bag could reduce reconstitution and dilution labor, preparation errors, and pharmacy handling. Its value depends on stability, packaging, shipping, and reimbursement economics.

Is Veklury exposed to biosimilar competition?

No. Veklury is a small-molecule remdesivir product, not a biologic. Competition would generally proceed through generic, hybrid, licensed, or other small-molecule regulatory pathways rather than biosimilar approval.

References

1. U.S. Food and Drug Administration. (2024). Veklury (remdesivir) prescribing information. Gilead Sciences, Inc.

2. U.S. Food and Drug Administration. (2023, July 14). FDA approves Veklury (remdesivir) for patients with severe renal impairment, including those on dialysis. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2020, October 22). FDA approves first treatment for COVID-19. https://www.fda.gov/

5. Gilead Sciences, Inc. (2024). 2023 annual report. https://www.gilead.com/annual-report